Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
Acute myeloid leukemia
CYP24A1
CYP27B1
vitamin D
vitamin D receptor
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
5
5
2022
medline:
19
8
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
Anti-cancer properties of vitamin D have been reported in studies. The aim of this study was to evaluate the expression of some key enzymes involved in vitamin D metabolism and the serum levels of related proteins. Fifty-four patients with acute myeloid leukemia (AML) and 55 eligible individuals were studied as the control group. The expression of VDR, CYP27B1, and CYP24A1 genes was measured. Serum levels of related proteins were quantified. The association between the studied variables and treatment outcomes: duration of fever and neutropenia, length of hospital stay, achievement of complete remission and overall survival has been investigated. Expression of CYP24A1 gene and serum levels of CYP27B1 and CYP24A1 proteins were significantly higher in the patient group. CYP24A1 gene expression, its blood concentrations and serum levels of CYP27B1 were significantly higher in the AML group. Vitamin D status and key enzymes did not show a strong change in AML patients neither did associate with treatment outcomes except CYP24A1.
Identifiants
pubmed: 35508323
doi: 10.1080/10428194.2022.2056174
doi:
Substances chimiques
Receptors, Calcitriol
0
VDR protein, human
0
Vitamin D
1406-16-2
CYP24A1 protein, human
EC 1.14.15.16
Vitamin D3 24-Hydroxylase
EC 1.14.15.16
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
EC 1.14.15.18
CYP27B1 protein, human
EC 1.14.15.18
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM